Financial, market and economic news

Eli Lilly’s Arthritis Drug Gets Emergency Use Approval For Treatment Of COVID-19

Eli Lilly And Co’s (NYSE: LLY) rheumatoid arthritis drug baricitinib has been issued an emergency use authorization, in combination with Gilead Sciences, Inc’s (NASDAQ: GILD) remdesivir, for the treatment of COVID-19 in adults and children who are hospitalized and require supplemental oxygen and other supportive ventilation measures. 

What Happened: The Food and Drug Administration said in a statement that baricitinib — sold under the brand name Olumiant — led to recovery within 29 days of initiating treatment compared to patients who only received remdesivir, in a clinical trial of hospitalized patients with COVID-19.

“The FDA’s emergency authorization of this combination therapy represents an incremental step forward in the treatment of COVID-19 in hospitalized patients, and …

Read More

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. AcceptRead More

Privacy & Cookies Policy